Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease

被引：0
|
作者：
Thomas, Mark [1 ]
机构：
[1] Royal Perth Hosp, Perth, Australia
来源：
MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2021.11.316
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
301
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [21] Efficacy, safety, and pharmacokinetics of CPL-01, an investigational long-acting ropivacaine, in bunionectomy: Results of a phase 2b study
    Xu, Hanghang Tommy
    Zimmerman, John
    Bertoch, Todd
    Chen, Lee
    Chen, Pj
    Onel, Erol
    JOURNAL OF FOOT & ANKLE SURGERY, 2025, 64 (02): : 150 - 156
  • [22] Interim Results from a Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy With Lentiviral Vector (Lenti-D) for Childhood Cerebral Adrenoleukodystrophy
    Eichler, Florian
    Duncan, Christine
    Thrasher, Adrian
    Shah, Ami
    Baruchel, Andre
    Paker, Asif
    Kohn, Donald
    Bratkovic, Drago
    Shamir, Esther
    Raymond, Gerald
    Gaspar, H. Bobby
    Amartino, Harnan
    Dalle, Jean-Hugues
    Larghero, Jerome
    Smith, Nicholas
    Musolino, Patricia
    Gissen, Paul
    Orchard, Paul
    Sankar, Raman
    De Oliveira, Satiro
    O'Meara, Tara
    Lund, Troy
    Miller, Weston
    Aubourg, Patrick
    Williams, David
    NEUROLOGY, 2016, 86
  • [23] Long-term efficacy and safety of migalastat compared to enzyme replacement therapy in Fabry disease: Phase 3 study results
    Hughes, Derralynn
    Bichet, Daniel G.
    Giugliani, Roberto
    Schiffmann, Raphael
    Wilcox, William R.
    Benjamin, Elfrida
    Castelli, Jeffrey P.
    Kirk, John
    Rutecki, Jasmine
    Skuban, Nina
    Yu, Julie
    Barth, Jay
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S57 - S57
  • [24] Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors
    Pasi, K. John
    Georgiev, Pencho
    Mant, Tim
    Lissitchkov, Toshko
    Creagh, Michael Desmond
    Bevan, David
    Austin, Steve
    Hay, Charles R.
    Hegemann, Inga
    Kazmi, Rashid
    Chowdary, Pratima
    Ragni, Margaret V.
    Soh, Chang-Heok
    Akinc, Akin
    Partisano, Angela M.
    Sorenson, Benny
    Rangarajan, Savita
    BLOOD, 2016, 128 (22)
  • [25] ELIGLUSTAT TARTRATE, AN INVESTIGATIONAL ORAL THERAPY FOR GAUCHER DISEASE TYPE 1: PHASE 2 RESULTS AFTER 2 YEARS
    Lukina, E.
    Peterschmitt, J.
    Watman, N.
    Arreguin, E.
    Pastores, G.
    Iastrebner, M.
    Dragosky, M.
    Rosenbaum, H.
    Phillips, M.
    Kaper, M.
    Singh, T.
    Puga, A. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 179 - 179
  • [26] Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years
    Peterschmitt, M. Judith
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Iastrebner, Marcelo
    Pastores, Gregory
    Avila Arreguin, Elsa
    Phillips, Mici
    Rosenbaum, Hanna
    Sysoeva, Elena
    Aguzzi, Rasha
    Ross, Leorah H.
    Puga, Ana Cristina
    BLOOD, 2011, 118 (21) : 506 - 507
  • [27] SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA
    Upadhyay, A. K.
    Qamar, H.
    Matloob, S.
    Chavali, M.
    CYTOTHERAPY, 2024, 26 (06) : S18 - S18
  • [28] The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
    Jacobsen, Leslie
    Kerner, Julie A.
    Ciotti, Rachel
    Golipour, Azadeh
    Yang, Josie
    Pfeifer, Richard
    Khan, Aneal
    Mason, Chris
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S51 - S52
  • [29] The GuardOne clinical trial: a first in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
    Ridha, E.
    Jones, J. J.
    Abrahamsen, I.
    Golipour, A.
    Pfeifer, R.
    Khan, A.
    Mason, C.
    Escolar, D.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A80 - A80
  • [30] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: POOLED RESULTS FROM THE PHASE 1 EXPLORER AND INTERIM PHASE 2 PATHFINDER STUDIES
    Vannucchi, A. M.
    Radia, D.
    DeAngelo, D.
    Deininger, M.
    Reiter, A.
    Lin, H. M.
    Dimitrijevic, S.
    Gotlib, J.
    HAEMATOLOGICA, 2022, 107 : 25 - 26
12345